Vertex Pharmaceuticals, Inc. (VRTX) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1162439,
    "name": "Vertex Pharmaceuticals, Inc.",
    "stock_name": "Vertex Pharmaceuticals, Inc.",
    "full_name": "Vertex Pharmaceuticals, Inc.",
    "name_url": "stocks-analysis/vertex-pharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "457.36",
    "chg": 24.21,
    "chgp": "5.59%",
    "dir": 1,
    "prev_price": "433.15",
    "mcapval": "101,338.41",
    "mcap": "Large Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US92532F1003",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "3.04 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vertex-pharmaceuticals-inc-1162439-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Vertex Pharmaceuticals, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vertex-pharmaceuticals-valuation-grade-downgraded-from-attractive-to-fair-amid-stock-price-increase-3667136",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/VertexPharmaceu_valuationdot_3667136.png",
        "date": "2025-11-03 16:00:53",
        "description": "Vertex Pharmaceuticals has adjusted its valuation amid changes in financial metrics and market positioning. The company reported a recent price of $425.57, with a negative stock return over the past year. Key indicators show it is currently loss-making, reflecting competitive dynamics within the pharmaceuticals and biotechnology sector."
      },
      {
        "title": "Vertex Pharmaceuticals Experiences Evaluation Revision Amid Mixed Market Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vertex-pharmaceuticals-technical-trend-shifts-from-bearish-to-mildly-bearish-amid-mixed-indicators-3601231",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/VertexPharmaceu_technicaldot_3601231.png",
        "date": "2025-10-07 20:28:36",
        "description": "Vertex Pharmaceuticals has recently revised its market evaluation, with its stock priced at $402.90. Over the past year, the company has seen an 11.51% decline, contrasting with the S&P 500's 17.82% return. Technical indicators present a mixed outlook, while Vertex has achieved a 54.38% return over five years."
      },
      {
        "title": "Is Vertex Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vertex-pharmaceuticals-inc-technically-bullish-or-bearish-3598920",
        "imagepath": "",
        "date": "2025-10-07 12:13:24",
        "description": "As of 3 October 2025, the technical trend for Vertex Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD is bearish, while the monthly MACD is mildly bearish, indicating a lack of strong upward momentum. The RSI shows no signal on the weekly chart but is bullish on the monthly, suggesting potential for upward movement over a longer time frame. However, the Bollinger Bands and KST are both mildly bearish on both weekly and monthly charts, reinforcing the bearish sentiment. The Dow Theory indicates a mildly bullish stance on the weekly but is mildly bearish on the monthly.\n\nIn terms of performance, Vertex has underperformed the S&P 500 across multiple periods, with a year-to-date return of 0.05% compared to the S&P 500's 14.18%, and a one-year return of -11.51% versus 17.82% for the index. Overall, the current technical stance is mildly bearish, with key indicators like the MACD ..."
      },
      {
        "title": "Is Vertex Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vertex-pharmaceuticals-inc-technically-bullish-or-bearish-3593646",
        "imagepath": "",
        "date": "2025-10-06 12:03:50",
        "description": "As of 3 October 2025, the technical trend for Vertex Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe and a mildly bearish reading on the daily moving averages. The monthly MACD and Bollinger Bands also indicate a mildly bearish sentiment. While the monthly RSI shows a bullish signal, the overall indicators suggest weakness. In terms of performance, Vertex has underperformed the S&P 500 over the past year, returning -11.08% compared to the S&P 500's 17.82%, and has also lagged in the year-to-date return with 0.15% versus 14.18%...."
      },
      {
        "title": "Is Vertex Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vertex-pharmaceuticals-inc-technically-bullish-or-bearish-3591719",
        "imagepath": "",
        "date": "2025-10-05 11:48:34",
        "description": "As of 3 October 2025, the technical trend for Vertex Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish signals, while the moving averages also reflect a mildly bearish outlook. The monthly MACD is mildly bearish, but the RSI shows a bullish signal, creating some divergence. The Dow Theory presents a mildly bullish signal on the weekly timeframe, but remains mildly bearish monthly. \n\nIn terms of performance, Vertex has underperformed the S&P 500 across multiple periods, with a year-to-date return of 0.15% compared to 14.18% for the index, and a one-year return of -11.08% versus 17.82%...."
      },
      {
        "title": "Is Vertex Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vertex-pharmaceuticals-inc-technically-bullish-or-bearish-3545459",
        "imagepath": "",
        "date": "2025-09-20 19:12:11",
        "description": "As of 11 September 2025, the technical trend for Vertex Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe and a bearish signal from Bollinger Bands across both weekly and monthly periods. The daily moving averages also indicate a bearish trend. While the monthly RSI shows bullish momentum, the overall indicators suggest weakness. \n\nIn terms of performance, Vertex has underperformed the S&P 500 across multiple periods, with a year-to-date return of -3.87% compared to the S&P 500's 12.22%, and a one-year return of -18.36% versus 17.14% for the benchmark...."
      },
      {
        "title": "Is Vertex Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vertex-pharmaceuticals-inc-overvalued-or-undervalued-3542168",
        "imagepath": "",
        "date": "2025-09-20 17:46:27",
        "description": "As of 4 August 2025, the valuation grade for Vertex Pharmaceuticals, Inc. has moved from risky to attractive, indicating a positive shift in its investment appeal. Despite this improvement, the company appears to be overvalued, particularly when considering its Price to Book Value of 7.01 and the EV to Sales ratio of 9.91, which are significantly higher than those of its peers. For instance, Merck & Co., Inc. has a more favorable EV to EBITDA of 12.15, while Pfizer Inc. stands out with an EV to EBITDA of 11.07, suggesting that Vertex may be priced too high relative to its earnings potential.\n\nIn terms of recent performance, Vertex has struggled, with a year-to-date return of -3.87% compared to the S&P 500's 12.22%, and a one-year return of -18.36% against the S&P 500's 17.14%. This underperformance reinforces the notion that the stock may be overvalued in the current market context...."
      }
    ],
    "total": 12,
    "sid": "1162439",
    "stock_news_url": "https://www.marketsmojo.com/news/vertex-pharmaceuticals-inc-1162439"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Vertex Pharmaceuticals, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-11-03 16:00:53

Vertex Pharmaceuticals has adjusted its valuation amid changes in financial metrics and market positioning. The company reported a recent price of $425.57, with a negative stock return over the past year. Key indicators show it is currently loss-making, reflecting competitive dynamics within the pharmaceuticals and biotechnology sector.

Vertex Pharmaceuticals Experiences Evaluation Revision Amid Mixed Market Indicators

2025-10-07 20:28:36

Vertex Pharmaceuticals has recently revised its market evaluation, with its stock priced at $402.90. Over the past year, the company has seen an 11.51% decline, contrasting with the S&P 500's 17.82% return. Technical indicators present a mixed outlook, while Vertex has achieved a 54.38% return over five years.

Is Vertex Pharmaceuticals, Inc. technically bullish or bearish?

2025-10-07 12:13:24

As of 3 October 2025, the technical trend for Vertex Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD is bearish, while the monthly MACD is mildly bearish, indicating a lack of strong upward momentum. The RSI shows no signal on the weekly chart but is bullish on the monthly, suggesting potential for upward movement over a longer time frame. However, the Bollinger Bands and KST are both mildly bearish on both weekly and monthly charts, reinforcing the bearish sentiment. The Dow Theory indicates a mildly bullish stance on the weekly but is mildly bearish on the monthly. In terms of performance, Vertex has underperformed the S&P 500 across multiple periods, with a year-to-date return of 0.05% compared to the S&P 500's 14.18%, and a one-year return of -11.51% versus 17.82% for the index. Overall, the current technical stance is mildly bearish, with key indicators like the MACD ...

Is Vertex Pharmaceuticals, Inc. technically bullish or bearish?

2025-10-06 12:03:50

As of 3 October 2025, the technical trend for Vertex Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe and a mildly bearish reading on the daily moving averages. The monthly MACD and Bollinger Bands also indicate a mildly bearish sentiment. While the monthly RSI shows a bullish signal, the overall indicators suggest weakness. In terms of performance, Vertex has underperformed the S&P 500 over the past year, returning -11.08% compared to the S&P 500's 17.82%, and has also lagged in the year-to-date return with 0.15% versus 14.18%....

Is Vertex Pharmaceuticals, Inc. technically bullish or bearish?

2025-10-05 11:48:34

As of 3 October 2025, the technical trend for Vertex Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish signals, while the moving averages also reflect a mildly bearish outlook. The monthly MACD is mildly bearish, but the RSI shows a bullish signal, creating some divergence. The Dow Theory presents a mildly bullish signal on the weekly timeframe, but remains mildly bearish monthly. In terms of performance, Vertex has underperformed the S&P 500 across multiple periods, with a year-to-date return of 0.15% compared to 14.18% for the index, and a one-year return of -11.08% versus 17.82%....

Is Vertex Pharmaceuticals, Inc. technically bullish or bearish?

2025-09-20 19:12:11

As of 11 September 2025, the technical trend for Vertex Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe and a bearish signal from Bollinger Bands across both weekly and monthly periods. The daily moving averages also indicate a bearish trend. While the monthly RSI shows bullish momentum, the overall indicators suggest weakness. In terms of performance, Vertex has underperformed the S&P 500 across multiple periods, with a year-to-date return of -3.87% compared to the S&P 500's 12.22%, and a one-year return of -18.36% versus 17.14% for the benchmark....

Is Vertex Pharmaceuticals, Inc. overvalued or undervalued?

2025-09-20 17:46:27

As of 4 August 2025, the valuation grade for Vertex Pharmaceuticals, Inc. has moved from risky to attractive, indicating a positive shift in its investment appeal. Despite this improvement, the company appears to be overvalued, particularly when considering its Price to Book Value of 7.01 and the EV to Sales ratio of 9.91, which are significantly higher than those of its peers. For instance, Merck & Co., Inc. has a more favorable EV to EBITDA of 12.15, while Pfizer Inc. stands out with an EV to EBITDA of 11.07, suggesting that Vertex may be priced too high relative to its earnings potential. In terms of recent performance, Vertex has struggled, with a year-to-date return of -3.87% compared to the S&P 500's 12.22%, and a one-year return of -18.36% against the S&P 500's 17.14%. This underperformance reinforces the notion that the stock may be overvalued in the current market context....

View All News